PsoriasisDX genetic Test for psoriatic arthritis is now available in Europe as a marked In Vitro Diagnostic Medical Device markup

Article date: 22 July 2010 -

Innovative research and development on molecular Dermatology DermaGenoma, Inc. announced today that the test genetic PsoriasisDX arthritis psoriatic (PsA) is now available as a marked CE under directive In Vitro Diagnostic product.

The genetic tests of PsoriasisDX helps identify those at high risk of develop psoriatic arthritis before they experience symptoms artríticas, providing the opportunity to reduce the joint damage in early medical intervention.

"We are excited to extend this revolutionary genetic testing progress to dermatologists in Europe,"said Andy Goren, CEO of DermaGenoma, Inc."It helps physicians identify treatments for patients".

Source:
DermaGenoma, Inc.

View the original article here